Our evaluation of the 0.19mg FAc implant delivered in a real-world setting, provides additional evidence that it is effective and safe in the treatment of patients with DMO, and can provide sustained benefit for patients with previously refractory disease.
Ranibizumab is a monoclonal antibody fragment that inhibits angiogenesis by inhibiting vascular endothelial
growth factor A, used as a treatment for patients with wet aged-related macular degeneration (ARMD). Adverse effects
from intravitreal Ranibizumab injections are well recognised. Macular hole formation following Ranibizumab injection is
a complication that has been recently reported in few case reports. We present a larger case series of five patients, who
developed full thickness macular holes (FTMH) after intravitreal Ranibizumab injections for treatment of wet ARMD that
we were aware of between 2009 and 2013.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.